A Study of Atezolizumab Compared With Platinum Doublet Chemotherapy for PD-L1 Highly Expressed, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
研究单位：[1]Hoffmann-La Roche[2]Xuanwu Hospital, Capital Medical University,Beijing City,China,100053[3]Beijing Chest Hospital[4]Oncology Department,Beijing,China,101149[5]The Third Xiangya Hospital Of Central South University,Changsha,China,410013[6]Changzhou First People's Hospital,Changzhou,China,213003[7]Sichuan Cancer Hospital,Chengdu City,China,610041[8]Daping Hospital of Third Military Medical University,Chongqing,China,400042[9]Fujian Cancer Hospital,Fuzhou,China,350014[10]Nanfang Hospital, Southern Medical University,Guangzhou,China,510515[11]Sir Run Run Shaw Hospital Zhejiang University,Hangzhou City,China,310016[12]The Second Affiliated Hospital, Zhejiang University,Hangzhou,China,310009[13]Harbin Medical University Cancer Hospital,Harbin,China,150081[14]Anhui Province Cancer Hospital,Hefei City,China,230031[15]The First Affiliated Hospital of Anhui Medical University,Hefei,China,230022[16]Shandong Cancer Hospital,Jinan,China,250117[17]The First Affiliated Hospital Of Jinzhou Medical University,Jinzhou City,China,121001[18]Yunnan Cancer Hospital,Kunming City,China,650118[19]Linyishi Cancer Hospital,Linyi City,China,276034[20]Nanjing Chest Hospital,Nanjing City,China,210029[21]Jiangsu Cancer Hospital,Nanjing City,China,211100[22]Shanghai Chest Hospital,Shanghai,China,200000[23]Cancer Hospital of Shantou University Medical College,Shantou,China,515041[24]Tianjin Medical University General Hospital,Tianjin,China,300052[25]Tianjin Cancer Hospital,Tianjin,China,300060[26]Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,China,430023[27]Renmin Hospital of Wuhan University,Wuhan,China,430060
研究目的：
This is a Phase III, randomized study to evaluate the efficacy and safety of atezolizumab compared with platinum-based chemotherapy consisting of a platinum agent (carboplatin or cisplatin) in combination with pemetrexed (non-squamous disease) OR gemcitabine or paclitaxel (squamous disease) in highly PD-L1 expressed, chemotherapy-naïve, EGFR/ALK wild type patients with stage IV non-squamous or squamous NSCLC.
